|
1
|
International Agency for Research on
Cancer (IARC). Global Cancer Observatory. IARC; Lyon: 2020,
simplehttps://gco.iarc.fr/
|
|
2
|
Oronsky B, Ray CM, Spira AI, Trepel JB,
Carter CA and Cottrill HM: A brief review of the management of
platinum-resistant-platinum-refractory ovarian cancer. Med Oncol.
34:1032017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Freimund AE, Beach JA, Christie EL and
Bowtell DDL: Mechanisms of drug resistance in high-grade serous
ovarian cancer. Hematol Oncol Clin North Am. 32:983–996. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gottesman MM, Lavi O, Hall MD and Gillet
JP: Toward a better understanding of the complexity of cancer drug
resistance. Annu Rev Pharmacol Toxicol. 56:85–102. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pandey MK, Prasad S, Tyagi AK, Deb L,
Huang J, Karelia DN, Amin SG and Aggarwal BB: Targeting cell
survival proteins for cancer cell death. Pharmaceuticals (Basel).
9:112016. View Article : Google Scholar
|
|
6
|
Hsieh IS, Huang WH, Liou HC, Chuang WJ,
Yang RS and Fu WM: Upregulation of drug transporter expression by
osteopontin in prostate cancer cells. Mol Pharmacol. 83:968–977.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Du B and Shim JS: Targeting
epithelial-mesenchymal transition (EMT) to overcome drug resistance
in cancer. Molecules. 21:9652016. View Article : Google Scholar
|
|
8
|
Elaskalani O, Razak NBA, Falasca M and
Metharom P: Epithelial-mesenchymal transition as a therapeutic
target for overcoming chemoresistance in pancreatic cancer. World J
Gastrointest Oncol. 9:37–41. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He Y, Xie H, Yu P, Jiang S and Wei L:
FOXC2 promotes epithelial-mesenchymal transition and cisplatin
resistance of non-small cell lung cancer cells. Cancer Chemother
Pharmacol. 82:1049–1059. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gimba ERP, Brum MCM and Nestal De Moraes
G: Full-length osteopontin and its splice variants as modulators of
chemoresistance and radioresistance (Review). Int J Oncol.
54:420–430. 2019.PubMed/NCBI
|
|
11
|
Ding K, Fan L, Chen S, Wang Y, Yu H, Sun
Y, Yu J, Wang L, Liu X and Liu Y: Overexpression of osteopontin
promotes resistance to cisplatin treatment in HCC. Oncol Rep.
34:3297–3303. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grbčić P, Tomljanović I, Klobučar M,
Kraljević Pavelić S, Lučin K and Sedić M: Dual sphingosine kinase
inhibitor SKI–II enhances sensitivity to 5-fluorouracil in
hepatocellular carcinoma cells via suppression of osteopontin and
FAK/IGF-1R signalling. Biochem Biophys Res Commun. 487:782–788.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ng L, Wan T, Chow A, Iyer D, Man J, Chen
G, Yau TC, Lo O, Foo CC, Poon JT, et al: Osteopontin overexpression
induced tumor progression and chemoresistance to oxaliplatin
through induction of stem-like properties in human colorectal
cancer. Stem Cells Int. 2015:2478922015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pang H, Cai L, Yang Y, Chen X, Sui G and
Zhao C: Knockdown of osteopontin chemosensitizes MDA-MB-231 cells
to cyclophosphamide by enhancing apoptosis through activating p38
MAPK pathway. Cancer Biother Radiopharm. 26:165–173. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qian C, Li P, Yan W, Shi L, Zhang J, Wang
Y, Liu H and You Y: Downregulation of osteopontin enhances the
sensitivity of glioma U251 cells to temozolomide and cisplatin by
targeting the NF-κB/Bcl-2 pathway. Mol Med Rep. 11:1951–1955. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gimba ER and Tilli TM: Human osteopontin
splicing isoforms: Known roles, potential clinical applications and
activated signaling pathways. Cancer Lett. 331:11–17. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hui T, Sørensen ES and Rittling SR:
Osteopontin binding to the alpha 4 integrin requires highest
affinity integrin conformation, but is independent of
post-translational modifications of osteopontin. Matrix Biol.
41:19–25. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kazanecki CC, Uzwiak DJ and Denhardt DT:
Control of osteopontin signaling and function by post-translational
phosphorylation and protein folding. J Cell Biochem. 102:912–924.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakamura KDM, Tilli TM, Wanderley JL,
Palumbo A Jr, Mattos RM, Ferreira AC, Klumb CE, Nasciutti LE and
Gimba ER: Osteopontin splice variants expression is involved on
docetaxel resistance in PC3 prostate cancer cells. Tumour Biol.
37:2655–2663. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bastos ACSF, Blunck CB, Emerenciano M and
Gimba ERP: Osteopontin and their roles in hematological
malignancies: Splice variants on the new avenues. Cancer Lett.
408:138–143. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Santoro JC, Bastos ACSF, Gimba ERP and
Emerenciano M: Reinforcing osteopontin as a marker of central
nervous system relapse in paediatric B-cell acute lymphoblastic
leukaemia: SPP1 splice variant 3 in the spotlight. Br J Haematol.
186:e88–e91. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sherman-Baust CA, Weeraratna AT, Rangel
LBA, Pizer ES, Cho KR, Schwartz DR, Shock T and Morin PJ:
Remodeling of the extracellular matrix through overexpression of
collagen VI contributes to cisplatin resistance in ovarian cancer
cells. Cancer Cell. 3:377–386. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yosifov DY, Reufsteck C, Konstantinov SM
and Berger MR: Interleukin-6, osteopontin and Raf/MEK/ERK signaling
modulate the sensitivity of human myeloma cells to
alkylphosphocholines. Leuk Res. 36:764–772. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Caldwell JT, Edwards H, Dombkowski AA,
Buck SA, Matherly LH, Ge Y and Taub JW: Overexpression of GATA1
confers resistance to chemotherapy in acute megakaryocytic
Leukemia. PLoS One. 8:e686012013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Niu ZH, Wang Y, Chun B, Li CX and Wu L:
Secretory clusterin (sCLU) overexpression is associated with
resistance to preoperative neoadjuvant chemotherapy in primary
breast cancer. Eur Rev Med Pharmacol Sci. 17:1337–1344.
2013.PubMed/NCBI
|
|
27
|
Wilks ST: Potential of overcoming
resistance to HER2-targeted therapies through the PI3K/Akt/mTOR
pathway. Breast. 24:548–555. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Montazami N, Aghapour M, Farajnia S and
Baradaran B: New insights into the mechanisms of multidrug
resistance in cancers. Cell Mol Biol (Noisy-le-grand). 61:70–80.
2015.PubMed/NCBI
|
|
29
|
Yang X, Yi C, Luo N and Gong C:
Nanomedicine to overcome cancer multidrug resistance. Curr Drug
Metab. 15:632–649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tilli TM, Franco VF, Robbs BK, Wanderley
JL, da Silva FR, de Mello KD, Viola JP, Weber GF and Gimba ER:
Osteopontin-c splicing isoform contributes to ovarian cancer
progression. Mol Cancer Res. 9:280–293. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee S, Choi EJ, Jin C and Kim DH:
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA
amplification contributes to cisplatin resistance in an ovarian
cancer cell line. Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou B, Sun C, Li N, Shan W, Lu H, Guo L,
Guo E, Xia M, Weng D, Meng L, et al: Cisplatin-induced CCL5
secretion from CAFs promotes cisplatin-resistance in ovarian cancer
via regulation of the STAT3 and PI3K/Akt signaling pathways. Int J
Oncol. 48:2087–2097. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kothari AN, Arffa ML, Chang V, Blackwell
RH, Syn WK, Zhang J, Mi Z and Kuo PC: Osteopontin-A Master
Regulator of Epithelial-Mesenchymal Transition. J Clin Med.
5:52016. View Article : Google Scholar
|
|
34
|
Zhu Y, Gao XM, Yang J, Xu D, Zhang Y, Lu
M, Zhang Z, Sheng YY, Li JH, Yu XX, et al: C-C chemokine receptor
type 1 mediates osteopontin-promoted metastasis in hepatocellular
carcinoma. Cancer Sci. 109:710–723. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Breier A, Gibalova L, Seres M, Barancik M
and Sulova Z: New insight into p-glycoprotein as a drug target.
Anticancer Agents Med Chem. 13:159–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Munoz JL, Walker ND, Scotto KW and
Rameshwar P: Temozolomide competes for P-glycoprotein and
contributes to chemoresistance in glioblastoma cells. Cancer Lett.
367:69–75. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Robey RW, Pluchino KM, Hall MD, Fojo AT,
Bates SE and Gottesman MM: Revisiting the role of ABC transporters
in multidrug-resistant cancer. Nat Rev Cancer. 18:452–464. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Luo SD, Chen YJ, Liu CT, Rau KM, Chen YC,
Tsai HT, Chen CH and Chiu TJ: Osteopontin involves cisplatin
resistance and poor prognosis in oral squamous cell carcinoma.
BioMed Res Int. 2015:5085872015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huang J, Chang S, Lu Y, Wang J, Si Y,
Zhang L, Cheng S and Jiang WG: Enhanced osteopontin splicing
regulated by RUNX2 is HDAC-dependent and induces invasive
phenotypes in NSCLC cells. Cancer Cell Int. 19:3062019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Davidson B, Tropé CG and Reich R:
Epithelial-mesenchymal transition in ovarian carcinoma. Front
Oncol. 2:332012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huang RYJ, Wong MK, Tan TZ, Kuay KT, Ng
AH, Chung VY, Chu YS, Matsumura N, Lai HC, Lee YF, et al: An EMT
spectrum defines an anoikis-resistant and spheroidogenic
intermediate mesenchymal state that is sensitive to e-cadherin
restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell
Death Dis. 4:e9152013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chebouti I, Kasimir-Bauer S, Buderath P,
Wimberger P, Hauch S, Kimmig R and Kuhlmann JD: EMT-like
circulating tumor cells in ovarian cancer patients are enriched by
platinum-based chemotherapy. Oncotarget. 8:48820–48831. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Carduner L, Leroy-Dudal J, Picot CR,
Gallet O, Carreiras F and Kellouche S: Ascites-induced shift along
epithelial-mesenchymal spectrum in ovarian cancer cells:
Enhancement of their invasive behavior partly dependant on αv
integrins. Clin Exp Metastasis. 31:675–688. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Techasen A, Loilome W, Namwat N, Dokduang
H, Jongthawin J and Yongvanit P: Cytokines released from activated
human macrophages induce epithelial mesenchymal transition markers
of cholangiocarcinoma cells. Asian Pac J Cancer Prev. 13
(Suppl):115–118. 2012.PubMed/NCBI
|
|
45
|
Sistigu A, Di Modugno F, Manic G and
Nisticò P: Deciphering the loop of epithelial-mesenchymal
transition, inflammatory cytokines and cancer immunoediting.
Cytokine Growth Factor Rev. 36:67–77. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rezaeifard S, Razmkhah M, Robati M,
Momtahan M and Ghaderi A: Cytokines, chemokines, and chemokine
receptors quantitative expressions in patients with ovarian cancer.
Iran J Med Sci. 40:225–232. 2015.PubMed/NCBI
|
|
47
|
Sullivan NJ, Sasser AK, Axel AE, Vesuna F,
Raman V, Ramirez N, Oberyszyn TM and Hall BM: Interleukin-6 induces
an epithelial-mesenchymal transition phenotype in human breast
cancer cells. Oncogene. 28:2940–2947. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fernando RI, Hamilton DH, Huang B and
Palena C: Interleukin-8 drives epithelial-mesenchymal transition of
human carcinomas. J Immunother Cancer. 1 (S1):1872013. View Article : Google Scholar
|
|
49
|
Zhang C, Ma K and Li WY: IL-6 promotes
cancer stemness and oncogenicity in U2OS and MG-63 osteosarcoma
cells by upregulating the OPN-STAT3 pathway. J Cancer.
10:6511–6525. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Learn PA, Yeh IT, McNutt M, Chisholm GB,
Pollock BH, Rousseau DL Jr, Sharkey FE, Cruz AB and Kahlenberg MS:
HER-2/neu expression as a predictor of response to neoadjuvant
docetaxel in patients with operable breast carcinoma. Cancer.
103:2252–2260. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Omarini C, Bettelli S, Caprera C,
Manfredini S, Caggia F, Guaitoli G, Moscetti L, Toss A, Cortesi L,
Kaleci S, et al: Clinical and molecular predictors of long-term
response in HER2 positive metastatic breast cancer patients. Cancer
Biol Ther. 19:879–886. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kwon MJ, Soh JS, Lim SW, Kang HS and Lim
H: HER2 as a limited predictor of the therapeutic response to
neoadjuvant therapy in locally advanced rectal cancer. Pathol Res
Pract. 215:910–917. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gerson JN, Skariah S, Denlinger CS and
Astsaturov I: Perspectives of HER2-targeting in gastric and
esophageal cancer. Expert Opin Investig Drugs. 26:531–540. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
El Dika I and Ilson DH: Current and future
therapies for targeting HER2 mutations in gastrointestinal cancer.
Expert Rev Anticancer Ther. 18:1085–1092. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Dong Y, Li W, Gu Z, Xing R, Ma Y, Zhang Q
and Liu Z: Inhibition of HER2-positive breast cancer growth by
blocking the HER2 signaling pathway with HER2-glycan-imprinted
nanoparticles. Angew Chem Int Ed Engl. 58:10621–10625. 2019.
View Article : Google Scholar : PubMed/NCBI
|
